Argenx's $1.7 Billion Quarter Is Buying a Pipeline It Hasn't Proven

$1.721 billion in product sales. Up 54% year over year. Up 13% from the second quarter.

Those are the numbers argenx put on Vyvgart in the third quarter, and they are the strongest argument that the FcRn franchise is still early. The same report showed operating profit of $486 million, roughly $80 million below the analyst estimate of about $565 million. The shares fell more than 2%.

The quarter forces a question investors have avoided while the sales line kept compounding: can a one-drug company spend its way into becoming an immunology platform before the market loses patience with the pipeline?

The Franchise Math: $1.72 Billion In, $1.27 Billion Out

Total operating expenses were $1.266 billion, against $805 million a year earlier. Research and development rose to $503 million from $359 million. Selling, general and administrative costs reached $598 million from $336 million, including about $150 million tied to the Forte Biosciences acquisition.

Net profit still rose to $506 million, or $7.80 per diluted share, from $344 million. Nine-month sales reached $4.534 billion, and nine-month operating profit reached $1.372 billion. Cash and current financial assets stood at $3.7 billion after argenx paid about $2.1 billion net for Forte.

The guidance matters more than the quarter. Combined R&D and SG&A are now expected to be about $4 billion in 2026, including the Forte transaction costs.

That is a company spending like a platform and earning like a franchise. The distinction is not academic. A franchise can cut costs when a trial fails. A platform has to keep funding the next one.

“Five years post-launch, we are still early in realizing Vyvgart’s potential across MG and CIDP.”— Karen Massey, CEO, argenx, Q3 2026 earnings call

What the UNITY Stop Actually Tested

On October 8, argenx discontinued the Phase 3 UNITY study of subcutaneous efgartigimod in moderate-to-severe Sjögren’s disease. An independent data monitoring committee stopped it for futility at an interim analysis, concluding the trial could not meet its primary endpoint: change in the clinical ESSDAI score at Week 48.

No new safety signals. The safety profile held; the efficacy signal did not.

The endpoint was a change in a composite disease-activity score at Week 48, not a single biomarker or symptom scale. William Blair had projected $1.4 billion in peak Sjögren’s sales before the stop.

Argenx says full data analysis will take months. That leaves investors with a familiar shape: another late-stage futility, booked before the sales engine showed any strain.

The same quarter brought a second pipeline correction. ALKIVIA, the Phase 3 study in immune-mediated necrotizing myopathy and dermatomyositis, showed a clear signal in both. It did not reach statistical significance in the DM subgroup, which was small. The FDA asked for confirmatory data, and argenx will run an additional registrational study in DM.

Forte, FB102, and the Price of a Second Pillar

$2.2 billion for Forte Biosciences bought argenx FB102, an anti-CD122 antibody aimed at IL-15 signaling. On the same day UNITY failed, argenx reported that FB102 hit the primary endpoint in a Phase 2 celiac disease trial and said it will move the drug into Phase 3.

The timing is the strategy. A company with one commercial engine needs a second one before the first shows its limits. FB102 also has Phase 1b data in vitiligo and ongoing work in alopecia areata.

Argenx expects 10 molecules in clinical development by the end of 2026. That is the platform claim in numerical form. The $2.2 billion price is the market’s estimate of what a second pillar is worth when the first one already generates $4.5 billion in nine months.

Five Launches, One Binary Readout

Management pointed to five possible launches in 2027. They include an IMNM submission by the end of 2026, a pediatric gMG decision in February 2027, an ocular gMG filing already submitted, and an autoinjector in the second half of the year.

CHRONICLE: argenx pipeline, 2026–2027
────────────────────────────
OCT 2026  ·  🧬  UNITY stopped; ALKIVIA positive in IMNM and DM
OCT 2026  ·  💰  FB102 hits Phase 2 celiac endpoint
◉ NOW     ·  💵  Q3 Vyvgart sales $1.72B, up 54% YoY
🔥 NEXT   ·  🧪  EMPASSION MMN readout, December 2026
2027      ·  🚀  Five potential launches

The harder test is empasiprubart. The Phase 3 EMPASSION study in multifocal motor neuropathy reads out in December 2026, and it is the first clean look at whether argenx can build a second franchise molecule of its own.

After that comes ADVANCE-NEXT in primary ITP in the first half of 2027, then the EMVIGORATE and EMNERGIZE studies in CIDP in the second half. Each one carries a number the market will price immediately.

The quarter answered the demand question. It did not answer the pipeline question.

As we wrote in October, oral immunology is where the next land grab is forming. The Matchpoint deal is the clearest recent example. Argenx is betting that subcutaneous biologics and a bought pipeline can hold the line long enough to meet it.